CAS OpenIR  > 生化工程国家重点实验室
Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation
Wang, Chunyue1,2; Zhang, Chun1,2; Li, Zenglan2; Yin, Shuang1,2,3; Wang, Qi2; Guo, Fangxia2; Zhang, Yao2; Yu, Rong1; Liu, Yongdong2; Su, Zhiguo2
2018-03-01
发表期刊BIOMACROMOLECULES
ISSN1525-7797
卷号19期号:3页码:773-781
摘要Nanoparticles based on the heavy chain of the human ferritin (HFn) are arousing growing interest in the field of drug delivery due to their exceptional characteristics. However, the unsatisfied plasma half life of HFn substantially limits its application as a delivery platform for antitumor agents. Herein we fused an albumin binding domain (ABD) variant that basically derives from the streptococcal protein G and possesses a long-acting characteristic in serum albumin to the N-terminus of the HFn for the aim of half-life extension. This ABD HFn construct was highly expressed and fully self-assembled into symmetrical and spherical structure in E. coli bacteria. The purified ABD HFn showed a similar particle size with wild-type HFn and also exhibited an extremely high binding affinity with human serum albumin. To evaluate the therapeutic potential of this ABD HFn construct in terms of half-life extension, we encapsulated a model antitumor agent doxorubicin (DOX) into the ABD HFn. Significantly outstanding loading efficacy of above 60 molecules doxorubicin for each ABD HFn cage was achieved. The doxorubicin-loaded ABD HFn nanoparticle was characterized and further compared with the recombinant HFn counterpart. The ABD-HFn/DOX nanoparticle showed dramatically improved stability and comparable cell uptake rate when compared with HFn/DOX counterpart. Pharmacokinetics study in Sprague Dawley rats showed that ABD HFn/DOX nanoparticle possessed significantly prolonged plasma half life of similar to 17.2 h, exhibiting nearly 19 times longer than that of free doxorubicin and 12 times for HFn/DOX. These optimal results indicated that fusion with ABD will be a promising strategy to extend the half life for protein-based nanoparticles.
文章类型Article
WOS标题词Science & Technology ; Life Sciences & Biomedicine ; Physical Sciences
DOI10.1021/acs.biomac.7b01545
收录类别SCI
语种英语
关键词[WOS]DRUG-DELIVERY ; SERUM-ALBUMIN ; PROTEIN ; PHARMACOKINETICS ; PLATFORM ; NANOTECHNOLOGY ; APOFERRITIN ; EXTENSION ; NANOCAGES ; TUMORS
WOS研究方向Biochemistry & Molecular Biology ; Chemistry ; Polymer Science
WOS类目Biochemistry & Molecular Biology ; Chemistry, Organic ; Polymer Science
项目资助者National Natural Science Foundation of China(21576267 ; Beijing Natural Science Foundation(2162041) ; Open Funding Project of the National Key Laboratory of Biochemical Engineering(2014KF-05) ; Major State Basic Research Development Program of China(2013CB733604) ; 81773623)
WOS记录号WOS:000427539600008
引用统计
被引频次:1[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.ipe.ac.cn/handle/122111/24071
专题生化工程国家重点实验室
作者单位1.Sichuan Univ, West China Sch Pharm, Minist Educ, Key Lab Drug Targeting & Drug Delivery Syst, Chengdu 610041, Sichuan, Peoples R China
2.Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China
3.Univ Adelaide, Sch Chem Engn, Adelaide, SA 5005, Australia
推荐引用方式
GB/T 7714
Wang, Chunyue,Zhang, Chun,Li, Zenglan,et al. Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation[J]. BIOMACROMOLECULES,2018,19(3):773-781.
APA Wang, Chunyue.,Zhang, Chun.,Li, Zenglan.,Yin, Shuang.,Wang, Qi.,...&Su, Zhiguo.(2018).Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation.BIOMACROMOLECULES,19(3),773-781.
MLA Wang, Chunyue,et al."Extending Half Life of H-Ferritin Nanoparticle by Fusing Albumin Binding Domain for Doxorubicin Encapsulation".BIOMACROMOLECULES 19.3(2018):773-781.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Wang, Chunyue]的文章
[Zhang, Chun]的文章
[Li, Zenglan]的文章
百度学术
百度学术中相似的文章
[Wang, Chunyue]的文章
[Zhang, Chun]的文章
[Li, Zenglan]的文章
必应学术
必应学术中相似的文章
[Wang, Chunyue]的文章
[Zhang, Chun]的文章
[Li, Zenglan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。